A double-virally-inactivated (Intercept–solvent/detergent) human platelet lysate for in vitro expansion of human mesenchymal stromal cells
Lassina Barro
International Ph.D. Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
Search for more papers by this authorYu-Ting Su
Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
Research Center for Cell Therapy and Regeneration Medicine, Taipei Medical University, Taipei, Taiwan
Search for more papers by this authorOuada Nebie
Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
Search for more papers by this authorYu-Wen Wu
Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
Search for more papers by this authorYen-Hua Huang
Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
Research Center for Cell Therapy and Regeneration Medicine, Taipei Medical University, Taipei, Taiwan
International Ph.D. Program in Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
Search for more papers by this authorMickey BC Koh
Stem Cell Transplantation Programme, St. George's University Hospitals NHS Foundation Trust, Tooting, London, SW17 0QT, United Kingdom
Cell Therapy Programme, Blood Services Group, Health Sciences Authority, Singapore
Search for more papers by this authorFolke Knutson
Clinical Immunology and Transfusion Medicine IGP, Uppsala University, Uppsala, Sweden
Search for more papers by this authorCorresponding Author
Thierry Burnouf
International Ph.D. Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
International Ph.D. Program in Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
Address reprint requests to: Thierry Burnouf, Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, 250 Wu-Xing Street, Taipei 11031, Taiwan; e-mail: [email protected]Search for more papers by this authorLassina Barro
International Ph.D. Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
Search for more papers by this authorYu-Ting Su
Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
Research Center for Cell Therapy and Regeneration Medicine, Taipei Medical University, Taipei, Taiwan
Search for more papers by this authorOuada Nebie
Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
Search for more papers by this authorYu-Wen Wu
Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
Search for more papers by this authorYen-Hua Huang
Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
Research Center for Cell Therapy and Regeneration Medicine, Taipei Medical University, Taipei, Taiwan
International Ph.D. Program in Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
Search for more papers by this authorMickey BC Koh
Stem Cell Transplantation Programme, St. George's University Hospitals NHS Foundation Trust, Tooting, London, SW17 0QT, United Kingdom
Cell Therapy Programme, Blood Services Group, Health Sciences Authority, Singapore
Search for more papers by this authorFolke Knutson
Clinical Immunology and Transfusion Medicine IGP, Uppsala University, Uppsala, Sweden
Search for more papers by this authorCorresponding Author
Thierry Burnouf
International Ph.D. Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
International Ph.D. Program in Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
Address reprint requests to: Thierry Burnouf, Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, 250 Wu-Xing Street, Taipei 11031, Taiwan; e-mail: [email protected]Search for more papers by this authorAbstract
BACKGROUND
Pooled human platelet lysate (HPL) can replace fetal bovine serum (FBS) as xeno-free supplement for ex vivo expansion of mesenchymal stromal cells (MSCs). We evaluate here whether a double-virally-inactivated HPL (DVI-HPL) prepared from expired Intercept-treated platelet concentrates (PCs) and treated by solvent/detergent (S/D) can be used for MSC expansion.
STUDY DESIGN AND METHODS
Expired Intercept-treated PCs in 65% platelet (PLT) additive solution were pooled and subjected to a 1% tri-n-butyl phosphate/1% Triton X-45 treatment followed by soybean oil, hydrophobic interaction chromatography purification, and sterile filtration. Bone marrow–derived MSCs (BM-MSCs) were expanded for four passages in growth medium containing 10% DVI-HPL, I-HPL (from Intercept-PC only), untreated HPL, and FBS. MSC morphology, doubling time, immunophenotype, immunosuppressive activity, and differentiation capacity were compared.
RESULTS
Expanded cells had typical spindle morphology and showed higher viability in all HPL conditions than in FBS. The DVI-HPL and FBS-expanded cells were morphologically larger than in I-HPL and HPL supplements. The cumulative population doubling was lower using DVI-HPL than with HPL and I-HPL, but significantly higher than using FBS. Immunophenotype was not affected by the supplements used. Immunosuppressive activity was maintained with all supplements. Differentiation capacity into chondrocytes and osteocytes was more effective in DVI-HPL but less toward adipocytes compared to other supplements.
CONCLUSIONS
Human PLT lysate made from Intercept-PCs subjected to S/D treatment may be an alternative to untreated HPL and to I-HPL for BM-MSC expansion. This finding reinforces the potential of HPL as a virally safe alternative to FBS for clinical grade MSC expansion protocols.
Supporting Information
| Filename | Description |
|---|---|
| trf15251-sup-0001-Supinfo.docxWord 2007 document , 25.8 KB | Appendix S1: Supporting information |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Chen MS, Wang TJ, Lin HC, et al. Four types of human platelet lysate, including one virally inactivated by solvent-detergent, can be used to propagate Wharton jelly mesenchymal stromal cells. N Biotechnol 2019; 49: 151-60.
- 2Dessels C, Durandt C, Pepper MS. Comparison of human platelet lysate alternatives using expired and freshly isolated platelet concentrates for adipose-derived stromal cell expansion. Platelets 2018; 29: 1-12.
- 3Jonsdottir-Buch S, Sigurgrimsdottir H, Lieder R, et al. Expired pathogen inactivated platelet concentrates support differentiation and immunomodulation of mesenchymal stromal cells in culture. J Tissue Eng Regen Med 2014; 8: 374.
- 4Glovinski PV, Herly M, Mathiasen AB, et al. Overcoming the bottleneck of platelet lysate supply in large-scale clinical expansion of adipose-derived stem cells: a comparison of fresh versus three types of platelet lysates from outdated buffy coat-derived platelet concentrates. Cytotherapy 2017; 19: 222-34.
- 5Le Blanc K, Samuelsson H, Lonnies L, et al. Generation of immunosuppressive mesenchymal stem cells in allogeneic human serum. Transplantation 2007; 84: 1055-9.
- 6Mizuno N, Shiba H, Ozeki Y, et al. Human autologous serum obtained using a completely closed bag system as a substitute for foetal calf serum in human mesenchymal stem cell cultures. Cell Biol Int 2006; 30: 521-4.
- 7Kocaoemer A, Kern S, Kluter H, et al. Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells 2007; 25: 1270-8.
- 8Doucet C, Ernou I, Zhang Y, et al. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 2005; 205: 228-36.
- 9Burnouf T, Strunk D, Koh M, et al. Human platelet lysate: replacing fetal bovine serum as a gold standard for human cell propagation? Biomaterials 2016; 76: 371-87.
- 10Bieback K, Hecker A, Kocaomer A, et al. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 2009; 27: 2331-41.
- 11Shih DT-B, Burnouf T. Preparation, quality criteria, and properties of human blood platelet lysate supplements for ex vivo stem cell expansion. N Biotechnol 2015; 32: 199-211.
- 12Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-7.
- 13Robertson JS. Bovine serum--regulatory issues. Dev Biol (Basel) 2006; 123: 269-72 discussion 91-308.
- 14Hill AF, Desbruslais M, Joiner S, et al. The same prion strain causes vCJD and BSE. Nature 1997; 389: 448-50-526.
10.1038/38925 Google Scholar
- 15Spees JL, Gregory CA, Singh H, et al. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther 2004; 9: 747-56.
- 16Heiskanen A, Satomaa T, Tiitinen S, et al. N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible. Stem Cells 2007; 25: 197-202.
- 17Perez Vaquero MA, Gorria C, Lezaun M, et al. Optimization of the management of platelet concentrate stocks in the Basque Country using mathematical simulation. Vox Sang 2016; 110: 369-75.
- 18Guan L, Tian X, Gombar S, et al. Big data modeling to predict platelet usage and minimize wastage in a tertiary care system. Proc Natl Acad Sci U S A 2017; 114: 11368-73.
- 19Whitaker B, Rajbhandary S, Harris A. The 2013 AABB blood collection, utilization, and patient blood management survey report. AABB: Bethesda (MD); 2015.
- 20Ellingson KD, Sapiano MR, Haass KA, et al. Continued decline in blood collection and transfusion in the U nited S tates-2015. Transfusion 2017; 57: 1588-98.
- 21Gstraunthaler G. Alternatives to the use of fetal bovine serum: serum-free cell culture. ALTEX 2003; 20: 275-81.
- 22van der Valk J, Mellor D, Brands R, et al. The humane collection of fetal bovine serum and possibilities for serum-free cell and tissue culture. Toxicol In Vitro 2004; 18: 1-12.
- 23Trento C, Bernardo ME, Nagler A, et al. Manufacturing mesenchymal stromal cells for the treatment of graft-versus-host disease: a survey among centers affiliated with the european society for blood and marrow transplantation. Biol Blood Marrow Transplant 2018; 24: 2365-70.
- 24Henschler R, Gabriel C, Schallmoser K, Burnouf T, Koh M.Human platelet lysate: current standards and future developments. Report on the Workshop organized by the Working Party on Cellular Therapies of the International Society of Blood Transfusion (ISBT). March 22-23, 2018, Zurich, Switzerland. Transfusion 2019; 59: 1407-13.
- 25Schallmoser K, Bartmann C, Rohde E, et al. Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion 2007; 47: 1436-46.
- 26Burnouf T, Radosevich M. Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev 2000; 14: 94-110.
- 27Burnouf T. Modern plasma fractionation. Transfus Med Rev 2007; 21: 101-17.
- 28 Anonymous. WHO recommendations for the production, quality control and regulation of plasma for fractionation. Geneva: World Health Organization; 2005 [accessed 2019 Jan 5] Available from http://www.who.int/bloodproducts2005.
- 29 Anonymous. CPMP note for guidance on plasma -derived medicinal products. CPMP/BWP/269/95 rev.4. Available from http://www.emea.eu.int [accessed 2019 Jan 5] 2009.
- 30Shih DTB, Chen JC, Chen WY, et al. Expansion of adipose tissue mesenchymal stromal progenitors in serum-free medium supplemented with virally inactivated allogeneic human platelet lysate. Transfusion 2011; 51: 770-8.
- 31Garraud O, Lozano M. Pathogen inactivation/reduction technologies for platelet transfusion: where do we stand? Transfus Clin Biol 2018; 25: 165-71.
- 32Fazzina R, Iudicone P, Mariotti A, et al. Culture of human cell lines by a pathogen-inactivated human platelet lysate. Cytotechnology 2016; 68: 1185-95.
- 33Jonsdottir-Buch SM, Sigurgrimsdottir H, Lieder R, et al. Expired and pathogen-inactivated platelet concentrates support differentiation and immunomodulation of mesenchymal stromal cells in culture. Cell Transplant 2015; 24: 1545-54.
- 34 Anonymous. INTERCEPT blood system for platelets - FDA. [accessed 2019 Jan 5] Available from https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/UCM427525.pdf, 2016:20.
- 35Strandberg G, Sellberg F, Sommar P, et al. Standardizing the freeze-thaw preparation of growth factors from platelet lysate. Transfusion 2017; 57: 1058-65.
- 36Kao Y-C, Bailey A, Samminger B, et al. Removal process of prion and parvovirus from human platelet lysates used as clinical-grade supplement for ex vivo cell expansion. Cytotherapy 2016; 18: 911-24.
- 37Jonsdottir-Buch SM, Lieder R, Sigurjonsson OE. Platelet lysates produced from expired platelet concentrates support growth and osteogenic differentiation of mesenchymal stem cells. PLoS One 2013; 8: e68984.
- 38Xiong G, Lingampalli N, Koltsov JCB, et al. Men and women differ in the biochemical composition of platelet-rich plasma. Am J Sports Med 2018; 46: 409-19.
- 39Evanson JR, Guyton MK, Oliver DL, et al. Gender and age differences in growth factor concentrations from platelet-rich plasma in adults. Mil Med 2014; 179: 799-805.
- 40Lommatzsch M, Zingler D, Schuhbaeck K, et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 2005; 26: 115-23.
- 41Bryant BJ, Klein HG. Pathogen inactivation: the definitive safeguard for the blood supply. Arch Pathol Lab Med 2007; 131: 719-33.
- 42 Anonymous. 5.2.12. Raw materials of biological origin for the production of cell-based and gene therapy medicinal products - European pharmacopoeia eu/en/ph-eur-9th-edition. Strasbourg: Council of Europe; 2016.
- 43Stühler A, Blümel J. Spezifische Aspekte zur Virussicherheit von Produktionshilfsstoffen für somatische Zelltherapie-Arzneimittel. Bundesgesundheitsbl 2015; 58: 1233-8.
10.1007/s00103-015-2238-y Google Scholar
- 44Ren J, Ward D, Chen S, et al. Comparison of human bone marrow stromal cells cultured in human platelet growth factors and fetal bovine serum. J Transl Med 2018; 16: 65.
- 45 Anonymous. European medicine agency - guideline on plasma-derived medicinal products. [accessed 2018 Dec 31] Available from https://www.ema.europa.eu/documents/scientific-guideline/guideline-plasma-derived-medicinal-products_en.pdf. London, UK, 2012.
- 46Irsch J, Lin L. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT blood system. Transfus Med Hemother 2011; 38: 19-31.
- 47Gallian P, Vignoli C, Dombey AM, et al. Inactivation of a European strain of West Nile virus in single- donor platelet concentrate using the INTERCEPT blood system. Vox Sang 2006; 91: 345-7.
- 48Pinna D, Sampson-Johannes A, Clementi M, et al. Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates. Transfus Med 2005; 15: 269-76.
- 49Schubert P, Johnson L, Marks DC, et al. Ultraviolet-based pathogen inactivation systems: untangling the molecular targets activated in platelets. Front Med (Lausanne) 2018; 5: 129.
- 50Henderson EE, Tudor G, Yang JY. Inactivation of the human immunodeficiency virus type 1 (HIV-1) by ultraviolet and X irradiation. Radiat Res 1992; 131: 169-76.
- 51Hauser L, Roque-Afonso AM, Beyloune A, et al. Hepatitis E transmission by transfusion of Intercept blood system-treated plasma. Blood 2014; 123: 796-7.
- 52Gowland P, Fontana S, Stolz M, et al. Parvovirus B19 passive transmission by transfusion of intercept(R) blood system-treated platelet concentrate. Transfus Med Hemother 2016; 43: 198-202.
- 53Kwon SY, Kim IS, Bae JE, et al. Pathogen inactivation efficacy of Mirasol PRT system and intercept blood system for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma. Vox Sang 2014; 107: 254-60.
- 54Dichtelmuller HO, Biesert L, Fabbrizzi F, et al. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from plasma protein therapeutics association member companies. Transfusion 2009; 49: 1931-43.
- 55Solheim BG, Rollag H, Svennevig JL, et al. Viral safety of solvent/detergent-treated plasma. Transfusion 2000; 40: 84-90.
- 56Keil SD, Bengrine A, Bowen R, et al. Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment. Transfusion 2015; 55: 1736-44.
- 57Gravemann U, Handke W, Lambrecht B, et al. Ultraviolet C light efficiently inactivates nonenveloped hepatitis A virus and feline calicivirus in platelet concentrates. Transfusion 2018; 58: 2669-74.
- 58Viau S, Eap S, Chabrand L, et al. Viral inactivation of human platelet lysate by gamma irradiation preserves its optimal efficiency in the expansion of human bone marrow mesenchymal stromal cells. Transfusion 2019; 59: 1069-10. https://doi.org/10.1111/trf.15205.
- 59Chou ML, Wu YW, Su CY, et al. Impact of solvent/detergent treatment of plasma on transfusion-relevant bacteria. Vox Sang 2012; 102: 277-84.
- 60Burnouf T, Chou ML, Wu YW, et al. Antimicrobial activity of platelet (PLT)-poor plasma, PLT-rich plasma, PLT gel, and solvent/detergent-treated PLT lysate biomaterials against wound bacteria. Transfusion 2013; 53: 138-46.
- 61Strunk D, Lozano M, Marks D, et al. International forum on GMP-grade human platelet lysate for cell propagation. Vox Sang 2018; 113: 80-7.
- 62Dantuluri MR, Mokkapati A, Nagumantri R, et al. In vitro studies of glucose concentrations for cell viability in normal and cancer cells. Int J Pharm Bio Sci 2018; 9: 5.
10.22376/ijpbs.2018.9.3.b77-81 Google Scholar
- 63Lan X, Field MS, Stover PJ. Cell cycle regulation of folate-mediated one-carbon metabolism. Wiley Interdiscip Rev Syst Biol Med 2018; 10: e1426.
- 64Fernández-Villa D, Jiménez Gómez-Lavín M, Abradelo C, et al. Tissue engineering therapies based on folic acid and other vitamin B derivatives functional mechanisms and current applications in regenerative medicine. Int J Mol Sci 2018; 19: 4068.
- 65Su CY, Kuo YP, Lin YC, et al. A virally inactivated functional growth factor preparation from human platelet concentrates. Vox Sang 2009; 97: 119-28.
- 66Tencerova M, Kassem M. The bone marrow-derived stromal cells: commitment and regulation of adipogenesis. Front Endocrinol 2016; 7: 127.
- 67Nishimura R, Hata K, Matsubara T, et al. Regulation of bone and cartilage development by network between BMP signalling and transcription factors. J Biochem 2012; 151: 247-54.
- 68Long F. Building strong bones: molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol 2012; 13: 27-38.
- 69Jonsdottir-Buch SM. PhD Thesis - Expired human platelets for mesenchymal stromal cell propagation. School of Health Science. Reykjavik, Iceland: University of Iceland; 2017.
- 70English K, Ryan J, Tobin L, et al. Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+ CD25Highforkhead box P3+ regulatory T cells. Clin Exp Immunol 2009; 156: 149-60.
- 71Han KH, Ro H, Hong JH, et al. Immunosuppressive mechanisms of embryonic stem cells and mesenchymal stem cells in alloimmune response. Transpl Immunol 2011; 25: 7-15.
- 72Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101: 3722-9.
- 73Renner P, Eggenhofer E, Rosenauer A, et al. Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function. Transplant Proc 2009; 41: 2607-11.
- 74Wang Y, Chen X, Cao W, et al. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol 2014; 15: 1009-16.
- 75Viau S, Chabrand L, Eap S, et al. Pathogen reduction through additive-free short-wave UV light irradiation retains the optimal efficacy of human platelet lysate for the expansion of human bone marrow mesenchymal stem cells. PloS One 2017; 12: e0181406.
Citing Literature
